MELBOURNE, Australia, Dec. 7 Data on Cytopia's (ASX: CYT) JAK2 inhibitor CYT387 will be presented at the 50th American Society of Hematology conference in San Francisco. The talk will be presented by Dr Thomas Bumm of Oregon Health and Sciences University and will overview the study of CYT387 in an in- vivo model of myeloproliferative disorders.
Full presentation details:
Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD
7am US PST, Tuesday December 9
Yerba Buena Ballroom Salon 8 (San Francisco Marriott).
Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and San Francisco, USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.
The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialed in Phase I and Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in early 2009.
SOURCE Cytopia Ltd